SCHEMBL402098

SCHEMBL402098

O=C1[C]=CCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6679609 0.72
SCHEMBL7699376 0.65
SCHEMBL18281404 0.60
SCHEMBL2140005 0.60
SCHEMBL11680869 0.56
SCHEMBL1555131 0.56
SCHEMBL9597190 0.53
SCHEMBL6556330 0.52
SCHEMBL5800702 0.52
SCHEMBL3370761 0.49

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9730448-B2 Tetrazolinone compound and use of same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-08-15 US claimed
US-20160205935-A1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-07-21 US claimed
EP-3040332-A1 TETRAZOLINONE COMPOUND AND USE OF SAME Sumitomo Chemical Company, Limited (JP) 2016-07-06 EP claimed
EP-1833826-B1 TRICYCLIC DELTA-OPIOID MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2009-05-27 EP claimed
EP-1765788-A2 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES MERCK PATENT GmbH (DE) 2007-03-28 EP claimed
WO-2005123688-A2 3-AMINOINDAZOLES MERCK PATENT GMBH (DE) 2005-12-29 WO claimed
US-20050203094-A1 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors AXYS PHARMACEUTICALS, INC. 2005-09-15 US claimed
EP-1474400-A1 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)] -6-HYDROXYBIPHENYL-3-YL DERIVATIVES AS FACTOR VIIA INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-11-10 EP claimed
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US claimed
US-20030216414-A1 Method for preventing tissue injury from hypoxia CELL THERAPEUTICS,INC. 2003-11-20 US claimed
WO-1998034601-A2 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1998-08-13 WO claimed
WO-1997045099-A1 USE OF LABDANUM FURANOID DITERPENOIDS FOR PREPARING COSMETIC OR PHARMACEUTICAL AND SKIN CELL CULTURE MEDIA COMPOSITIONS LVMH RECHERCHE (FR) 1997-12-04 WO claimed
EP-0739203-A1 METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF CELL THERAPEUTICS, INC. (US) 1996-10-30 EP claimed
EP-0728003-A1 METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA CELL THERAPEUTICS, INC. (US) 1996-08-28 EP claimed
EP-0676958-A1 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1995-10-18 EP claimed
WO-1995019171-A1 METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF CELL THERAPEUTICS, INC. (US) 1995-07-20 WO claimed
WO-1995013075-A1 METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA CELL THERAPEUTICS, INC. (US) 1995-05-18 WO claimed
WO-1995012396-A1 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1995-05-11 WO claimed
US-5158946-A Antibiotics, bactericides BEECHAM GROUP P.L.C. (GB) 1992-10-27 US claimed
EP-0418020-A2 Cephalosporinderivatives, process for their preparation and pharmaceutical compositions BEECHAM GROUP PLC (GB) 1991-03-20 EP claimed